famh-161 Antibody

What is ALF-161 antibody and what targets does it recognize?

ALF-161 is a monoclonal antibody that specifically reacts with mouse interleukin-1alpha (IL-1alpha), a 17 kDa cytokine. Mouse IL-1alpha is also known by several other names including Lymphocyte Activating Factor (LAF), Endogenous Pyrogen (EP), Leukocyte Endogenous Mediator (LEM), and Mononuclear Cell Factor (MCF). This antibody specifically targets IL-1alpha, which shares only 23% amino acid homology with IL-1beta, making it suitable for distinguishing between these related cytokines in experimental contexts .

What cell types produce IL-1alpha that can be detected using ALF-161?

IL-1alpha is produced by a diverse range of cells in the immune system. The primary producers include macrophages and dendritic cells, but T cells, B cells, and various other immune cells also synthesize this cytokine. ALF-161 can detect IL-1alpha from these cellular sources in mouse samples. Understanding the cellular source of IL-1alpha is critical when designing experiments to evaluate inflammatory responses or immune activation pathways .

What are the validated applications for ALF-161 antibody?

The ALF-161 antibody has been validated for multiple research applications:

• ELISA capture (validated concentration range: 1-4 μg/mL)

• ELISPOT capture

• Neutralization assays (0.031 μg/mL inhibits 50% of biological effects of 4.0 ng/mL mouse IL-1alpha)

• Intracellular staining for flow cytometry

Each application has been specifically tested to ensure optimal performance, with ELISA and neutralization activities having defined quantitative parameters to guide experimental design .

How should I optimize ALF-161 for use in sandwich ELISA?

When using ALF-161 as a capture antibody for sandwich ELISA to detect mouse IL-1alpha, follow these methodological considerations:

• Optimal coating concentration: Use 1-4 μg/mL of ALF-161 antibody for plate coating

• Detection system: Pair with biotin anti-mouse IL-1alpha polyclonal antibody (catalog #13-7111)

• Standard curve preparation: Create doubling dilutions of recombinant mouse IL-1alpha (catalog #14-8011) ranging from 1000 pg/mL down to 8 pg/mL

• Quality control: Include both positive and negative controls in each assay

• Optimization: Determine the optimal antibody concentration for your specific sample type and experimental conditions

This approach ensures a sensitive and reproducible detection system for quantifying mouse IL-1alpha in experimental samples .

What considerations are important when using ALF-161 for neutralization assays?

For neutralization experiments using ALF-161:

• Titration: ALF-161 at 0.031 μg/mL has been shown to inhibit 50% of the biological effects of 4.0 ng/mL mouse IL-1alpha in a D10 cell proliferation assay

• Pre-incubation: Mix the antibody with recombinant IL-1alpha before adding to cell culture to ensure neutralization

• Positive controls: Include relevant positive controls such as heat-inactivated IL-1alpha

• Dose-response assessment: Perform a dose-response curve to determine optimal neutralization parameters for your specific experimental model

• Monitoring: Assess multiple downstream effects of IL-1alpha signaling to confirm complete neutralization

This methodical approach allows for reliable neutralization of IL-1alpha biological activity in functional assays .

What quality control measures ensure ALF-161 antibody reliability?

Several quality control measures have been implemented to ensure ALF-161 reliability:

• LAL assay verification: The antibody has been tested to confirm low endotoxin levels, preventing experimental artifacts from contaminants

• Functional validation: Tested in bioassays for neutralization of mouse IL-1alpha bioactivity with specific metrics for inhibitory concentration

• ELISA testing: Validated as a capture antibody with defined parameters

• Filtration: Subjected to 0.2 μm post-manufacturing filtration to ensure sterility

• Reproducibility testing: Performance consistency evaluated across multiple lots

These comprehensive quality control measures ensure experimental reliability and reproducibility when using this antibody .

How should researchers implement proper controls when using antibodies like ALF-161?

Based on current antibody validation standards, researchers should implement the following controls:

• Knockout/knockdown validation: When possible, use IL-1alpha knockout cells or tissues as negative controls

• Isotype controls: Include appropriate isotype-matched control antibodies in flow cytometry and other applications

• Biological controls: Use samples with known high and low expression of IL-1alpha

• Cross-reactivity testing: Verify specificity by testing against similar cytokines, particularly IL-1beta

• Technical replicates: Perform at least three independent experiments to ensure reproducibility

• Recombinant protein controls: Use purified recombinant IL-1alpha as a positive control

These practices align with recommendations from antibody characterization experts and enhance experimental rigor and reproducibility .

How can ALF-161 be incorporated into multiparameter immunophenotyping experiments?

For advanced immunophenotyping experiments incorporating ALF-161:

• Panel design: Combine with antibodies against other cytokines (IL-6, TNF-α, IL-18) and cell surface markers for comprehensive immune profiling

• Fixation/permeabilization optimization: For intracellular staining, optimize fixation protocols to preserve both surface markers and intracellular IL-1alpha

• Sequential staining: Consider sequential staining approaches (surface markers followed by intracellular cytokines)

• Spectral overlap: Account for spectral overlap when designing multicolor panels

• Single-cell analysis: Integrate with single-cell analytical technologies for higher resolution of cellular heterogeneity

• Stimulation protocols: Standardize cellular stimulation protocols to induce IL-1alpha production consistently

These advanced approaches enable complex analysis of IL-1alpha in relation to other immune parameters in diverse experimental settings .

What are the considerations for using ALF-161 in tissue-specific inflammation models?

When adapting ALF-161 for tissue-specific inflammation research:

• Tissue digestion protocols: Optimize digestion methods to preserve IL-1alpha epitopes while achieving sufficient cellular dissociation

• Background reduction: Implement blocking strategies to minimize non-specific binding in tissue samples

• Penetration considerations: For immunohistochemistry, optimize antigen retrieval and antibody penetration protocols

• Co-localization studies: Combine with cell-type specific markers to identify IL-1alpha-producing cells in tissue contexts

• Quantification methods: Develop standardized approaches for quantifying IL-1alpha expression in tissue sections or homogenates

• Control tissues: Include appropriate tissue controls, including those from IL-1alpha-deficient animals

These methodological considerations ensure reliable detection of IL-1alpha in complex tissue environments where inflammation dynamics are being studied .

How should researchers address inconsistent results when using ALF-161 in ELISA applications?

When troubleshooting inconsistent ELISA results:

• Antibody storage: Verify proper storage conditions (2-8°C) and avoid freeze-thaw cycles

• Protocol standardization: Ensure consistent timing for incubation steps and washing procedures

• Blocking optimization: Test different blocking reagents to reduce background signal

• Standard curve validation: Prepare fresh standards for each assay and verify linear range

• Sample preparation: Standardize sample collection, processing, and storage conditions

• Batch effects: Include internal controls across multiple plates to normalize inter-assay variation

• Temperature control: Maintain consistent temperature during critical assay steps

These systematic troubleshooting approaches can identify sources of variability and improve reproducibility in IL-1alpha quantification experiments .

What strategies can resolve weak or absent signals when using ALF-161 for intracellular staining?

To address suboptimal results in intracellular staining applications:

• Stimulation protocol: Optimize cell stimulation conditions to enhance IL-1alpha production

• Fixation/permeabilization: Test different fixation reagents and incubation times

• Antibody titration: Perform detailed titration experiments to determine optimal concentration

• Signal amplification: Consider secondary antibody or amplification systems if direct detection is insufficient

• Cell viability: Implement viability dyes to exclude dead cells that may contribute to non-specific staining

• Kinetics assessment: Evaluate IL-1alpha expression at multiple time points after stimulation

• Protein transport inhibitors: Optimize use of protein transport inhibitors (like Brefeldin A) to accumulate intracellular cytokines

This structured approach helps researchers systematically identify and address factors affecting intracellular IL-1alpha detection using flow cytometry .

How should researchers interpret ALF-161 neutralization assay results in the context of complex inflammatory models?

When interpreting neutralization assay data:

• Dose-response relationship: Establish complete dose-response curves to accurately determine IC50 values

• Biological context: Consider that 0.031 μg/mL of ALF-161 inhibits 50% of the biological effects of 4.0 ng/mL mouse IL-1alpha in D10 cell proliferation assays, but this may vary in other systems

• Temporal dynamics: Analyze neutralization efficacy across different time points

• Pathway specificity: Confirm IL-1alpha-specific effects by measuring multiple downstream signaling markers

• Redundancy mechanisms: Consider compensatory mechanisms that may offset IL-1alpha neutralization

• Statistical analysis: Apply appropriate statistical methods to determine significance of neutralization effects

This comprehensive analytical approach enables more accurate interpretation of the biological significance of IL-1alpha neutralization in complex experimental systems .

What considerations are important when comparing data generated using different antibody lots or alternative anti-IL-1alpha antibodies?

When performing comparative analyses:

• Lot-to-lot validation: Always validate new antibody lots against previous ones using standard samples

• Epitope differences: Consider that different antibodies may recognize distinct epitopes on IL-1alpha

• Affinity variations: Account for differences in binding affinity that may affect sensitivity

• Application-specific performance: An antibody performing well in ELISA may not work equally well in flow cytometry

• Normalization strategies: Develop robust normalization methods when comparing data across antibodies

• Metadata documentation: Maintain comprehensive records of antibody details (lot, clone, vendor) with experimental data

These systematic comparison strategies help researchers account for technical variables when integrating data generated using different antibody reagents .

How might recombinant antibody technology impact the future use and reliability of antibodies like ALF-161?

The evolution toward recombinant antibody technology offers several advantages:

• Sequence-defined production: Recombinant antibodies with known sequences provide consistent performance across batches

• Genetic modification potential: Enables engineering of antibodies with enhanced properties (increased affinity, reduced background)

• Reproducibility improvement: Eliminates batch-to-batch variation inherent in hybridoma-derived antibodies

• Open science potential: Antibody sequences can be shared, allowing independent production and validation

• Format adaptability: Enables production of various antibody formats (scFv, Fab, full IgG) from the same binding domain

As demonstrated by initiatives like NeuroMab, converting traditional monoclonal antibodies to recombinant formats and making sequences publicly available significantly enhances research reproducibility while maintaining intellectual property considerations .

What novel applications might emerge for IL-1alpha detection using advanced detection technologies?

Emerging approaches for IL-1alpha research include:

• Single-cell cytokine secretion analysis: Combining ALF-161 with microfluidic or droplet-based single-cell technologies

• Multiplexed imaging: Implementing ALF-161 in multiplexed imaging platforms for spatial analysis of IL-1alpha in tissues

• Proximity ligation adaptations: Modifying antibodies for proximity ligation assays to study IL-1alpha interactions with receptor complexes

• In vivo imaging applications: Developing conjugates suitable for in vivo tracking of IL-1alpha production

• Mass cytometry integration: Incorporating metal-labeled ALF-161 into CyTOF panels for high-dimensional analysis

• Biosensor development: Creating continuous monitoring systems for IL-1alpha using antibody-based biosensors

These innovative approaches expand the utility of IL-1alpha detection beyond traditional applications and provide new insights into inflammatory processes .